Isoprostanes, biomarkers of lipid peroxidation in humans. Part 2: Quantification methods;Les isoprostanes, biomarqueurs de peroxydation lipidique chez l'homme. Partie 2: Méthodes de quantification

Pathologie Biologie

Volumn 53, Issue 6, 2005, Pages 356-363

  Berdeaux, O ^a   Scruel, O ^a   Durand, T ^b   Cracowski, J L ^c  

^a CEMAGREF   (France)

^b CNRS   (France)

^c UNIV GRENOBLE ALPES   (France)

Author keywords

Immunoassay; Isoprostane; Lipid peroxidation; Mass spectrometry; Neuroprostane; Quantitative analysis

Indexed keywords

BIOLOGICAL MARKER; FREE RADICAL; ISOPROSTANE; POLYUNSATURATED FATTY ACID;

CHROMATOGRAPHY; EXTRACTION; HUMAN; IMMUNOLOGY; LIPID PEROXIDATION; MASS SPECTROMETRY; METHODOLOGY; OXIDATIVE STRESS; PURIFICATION; RELIABILITY; REVIEW;

EID: 21744433692     PISSN: 03698114     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.patbio.2004.10.006     Document Type: Short Survey

References (48)

1. L.J. Roberts 2nd, and J.D. Morrow The generation and actions of isoprostanes Biochim. Biophys. Acta 1345 1997 121 135
2. R.J. Waugh, J.D. Morrow, L.J. Roberts 2nd, and R.C. Murphy Identification and relative quantitation of F2-isoprostane regioisomers formed in vivo in the rat Free Radic. Biol. Med. 23 1997 943 954
3. H. Li, J.A. Lawson, M. Reilly, M. Adiyaman, S.W. Hwang, and J. Rokach Quantitative high performance liquid chromatography/tandem mass spectrometric analysis of the four classes of F(2)-isoprostanes in human urine Proc. Natl. Acad. Sci. USA 96 1999 13381 13386
4. J.A. Lawson, J. Rokach, and G.A. FitzGerald Isoprostanes: formation, analysis and use as indices of lipid peroxidation in vivo J. Biol. Chem. 274 1999 24441 24444
5. J.D. Morrow, and L.J. Roberts 2nd Mass spectrometric quantification of F2-isoprostanes in biological fluids and tissues as measure of oxidant stress Methods Enzymol. 300 1999 3 12
6. J. Proudfoot, A. Barden, T.A. Mori, V. Burke, K.D. Croft, and L.J. Beilin Measurement of urinary F(2)-isoprostanes as markers of in vivo lipid peroxidation-A comparison of enzyme immunoassay with gas chromatography/mass spectrometry Anal. Biochem. 272 1999 209 215
7. A. Ferretti, and V.P. Flanagan Isolation and measurement of urinary 8-iso-prostaglandin F2alpha by high-performance liquid chromatography and gas chromatography-mass spectrometry J. Chromatogr. B Biomed. Sci. Appl. 694 1997 271 276
8. A. Bachi, E. Zuccato, M. Baraldi, R. Fanelli, and C. Chiabrando Measurement of urinary 8-Epi-prostaglandin F2alpha, a novel index of lipid peroxidation in vivo, by immunoaffinity extraction/gas chromatography-mass spectrometry. Basal levels in smokers and nonsmokers Free Radic. Biol. Med. 20 1996 619 624
9. T.A. Mori, K.D. Croft, I.B. Puddey, and L.J. Beilin An improved method for the measurement of urinary and plasma F2-isoprostanes using gas chromatography-mass spectrometry Anal. Biochem. 268 1999 117 125
10. J.D. Morrow, K.E. Hill, R.F. Burk, T.M. Nammour, K.F. Badr, and L.J. Roberts 2nd A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism Proc. Natl. Acad. Sci. USA 87 1990 9383 9387
11. M.F. Walter, J.B. Blumberg, G.G. Dolnikowski, and G.J. Handelman Streamlined F2-isoprostane analysis in plasma and urine with high-performance liquid chromatography and gas chromatography/mass spectroscopy Anal. Biochem. 280 2000 73 79
12. D. Tsikas Application of gas chromatography-mass spectrometry and gas chromatography-tandem mass spectrometry to assess in vivo synthesis of prostaglandins, thromboxane, leukotrienes, isoprostanes and related compounds in humans J. Chromatogr. B Biomed. Sci. Appl. 717 1998 201 245
13. J. Nourooz-Zadeh, N.K. Gopaul, S. Barrow, A.I. Mallet, and E.E. Anggard Analysis of F2-isoprostanes as indicators of non-enzymatic lipid peroxidation in vivo by gas chromatography-mass spectrometry: development of a solid-phase extraction procedure J. Chromatogr. B Biomed. Appl. 667 1995 199 208
14. J. Nourooz-Zadeh Gas chromatography-mass spectrometry assay for measurement of plasma isoprostanes Methods Enzymol. 300 1999 13 17
15. D. Pratico, O.P. Barry, J.A. Lawson, M. Adiyaman, S.W. Hwang, and S.P. Khanapure IPF2alpha-I: an index of lipid peroxidation in humans Proc. Natl. Acad. Sci. USA 95 1998 3449 3454
16. J. Nourooz-Zadeh, and P.F. Pereira 2) isoprostanes, potential specific markers of oxidative damage in human retina Ophthalmic Res. 32 2000 133 137
17. I.N. Guha, and K. Moore F2-isoprostanes and the liver Prostaglandins Other Lipid Mediat 72 2003 73 84
18. N. Delanty, M. Reilly, D. Pratico, D.J. FitzGerald, J.A. Lawson, and G.A. FitzGerald 8-Epi PGF2 alpha: specific analysis of an isoeicosanoid as an index of oxidant stress in vivo Br. J. Clin. Pharmacol. 42 1996 15 19
19. 2α excretion in man J. Pharmacol. Exp. Ther. 275 1995 94 100
20. D. Tsikas, E. Schwedhelm, J. Fauler, F.M. Gutzki, E. Mayatepek, and J.C. Frolich Specific and rapid quantification of 8-iso-prostaglandin F2alpha in urine of healthy humans and patients with Zellweger syndrome by gas chromatography-tandem mass spectrometry J. Chromatogr. B Biomed. Sci. Appl. 716 1998 7 17
21. M. Richelle, M.E. Turini, R. Guidoux, S. Ḿtairon, and L.B. Fay Gas chromatography-tandem mass spectrometry determination of 8-iso-PGF2a, a biomarker of in vivo lipid peroxidation, in human plasma and urine European J. of Mass Spectrometry 7 2001 427 432
22. H. Schweer, B. Watzer, H.W. Seyberth, and R.M. Nusing Improved quantification of 8-epi-prostaglandin F2α and F2-isoprostane by gas chromatography/triple-stage quadrupole mass spectrometry: partial Cyclooxygenase-dependant formation of 8-epi-prostaglandin F2α in humans J. Mass Spectrom. 32 1997 1362 1370
23. C. Signorini, M. Comporti, and G. Giorgi Ion trap tandem mass spectrometric determination of F2-isoprostanes J. Mass Spectrom 38 2003 1067 1074
24. J. Bessard, J.L. Cracowski, F. Stanke-Labesque, and G. Bessard Determination of isoprostaglandin F2alpha type III in human urine by gas chromatography-electronic impact mass spectrometry. Comparison with enzyme immunoassay J. Chromatogr B. Biomed Sci. Appl. 754 2001 333 343
25. T. Obata, K. Tomaru, T. Nagakura, Y. Izumi, and T. Kawamoto Smoking and oxidant stress: assay of isoprostane in human urine by gas chromatography-mass spectrometry J. Chromatogr. B Biomed. Sci. Appl. 746 2000 11 15
26. T. Obata, T. Nagakura, H. Maeda, K. Yamashita, and K. Maekawa Simultaneous assay of prostaglandins and thromboxane in the cerebrospinal fluid by gas chromatography-mass spectrometry-selected ion monitoring J. Chromatogr. B Biomed. Sci. Appl. 731 1999 73 81
27. T. Obata, Y. Sakurai, Y. Kase, Y. Tanifuji, and T. Horiguchi Simultaneous determination of endocannabinoids (arachidonylethanolamide and 2-arachidonylglycerol) and isoprostane (8-epiprostaglandin F2alpha) by gas chromatography-mass spectrometry-selected ion monitoring for medical samples J. Chromatogr. B Analyt. Technol. Biomed. Life Sci 792 2003 131 140
28. K.A. Harrison, and R.C. Murphy Isoleukotrienes are biologically active free radical products of lipid peroxidation J. Biol. Chem. 270 1995 17273 17278
29. N. Ohashi, and M. Yoshikawa Rapid and sensitive quantification of 8-isoprostaglandin F2alpha in human plasma and urine by liquid chromatography-electrospray ionization mass spectrometry J. Chromatogr. B Biomed. Sci. Appl. 746 2000 17 24
30. J.A. Lawson, H. Li, J. Rokach, M. Adiyaman, S.W. Hwang, and S.P. Khanapure Identification of two major F2 isoprostanes, 8,12-iso- and 5-epi-8, 12-iso-isoprostane F2alpha-VI, in human urine J. Biol. Chem. 273 1998 29295 29301
31. S. Basu Metabolism of 8-iso-prostaglandin F2alpha FEBS Lett. 428 1998 32 36
32. L.J. Roberts, and J.D. Morrow Measurement of F(2)-isoprostanes as an index of oxidative stress in vivo Free Radic. Biol. Med. 28 2000 505 513
33. J.D. Morrow, and L.J. Roberts 2nd Mass spectrometric quantification of prostanoids: F2-Isoprostane produced by non-cyclooxygenase free radiacl-catalysed mechanism Methods Enzymol. 233 1994 163 175
34. N.K. Gopaul, E.E. Anggard, A.I. Mallet, D.J. Betteridge, S.P. Wolff, and J. Nourooz-Zadeh Plasma 8-epi-PGF2 alpha levels are elevated in individuals with non-insulin dependent diabetes mellitus FEBS Lett. 368 1995 225 229
35. Z. Zhao, N.M. Hjelm, C.W. Lam, and C.S. Ho One-step solid-phase extraction procedure for F(2)-isoprostanes Clin. Chem. 47 2001 1306 1308
36. E. Schwedhelm, D. Tsikas, T. Durand, F.M. Gutzki, A. Guy, and J.C. Rossi Tandem mass spectrometric quantification of 8-iso-prostaglandin F2alpha and its metabolite 2,3-dinor-5,6-dihydro-8-iso-prostaglandin F2alpha in human urine J. Chromatogr. B Biomed. Sci. Appl. 744 2000 99 112
37. J.D. Morrow, T.M. Harris, and L.J. Roberts 2nd Noncyclooxygenase oxidative formation of a series of novel prostaglandins: analytical ramifications for measurement of eicosanoids Anal. Biochem. 184 1990 1 10
38. J.D. Morrow, B. Frei, A.W. Longmire, J.M. Gaziano, S.M. Lynch, and Y. Shyr Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage N. Engl. J. Med. 332 1995 1198 1203
39. L.J. Roberts 2nd, K.P. Moore, W.E. Zackert, J.A. Oates, and J.D. Morrow Identification of the major urinary metabolite of the F2-isoprostane 8-iso-prostaglandin F2alpha in humans J. Biol. Chem. 271 1996 20617 20620
40. C. Chiabrando, A. Valagussa, C. Rivalta, T. Durand, A. Guy, and E. Zuccato Identification and measurement of endogenous beta-oxidation metabolites of 8-epi-Prostaglandin F2alpha J. Biol. Chem. 274 1999 1313 1319
41. A. Burke, J.A. Lawson, E.A. Meagher, J. Rokach, and G.A. FitzGerald Specific analysis in plasma and urine of 2,3-dinor-5, 6-dihydro-isoprostane F(2alpha)-III, a metabolite of isoprostane F(2alpha)-III and an oxidation product of gamma-linolenic acid J. Biol. Chem. 275 2000 2499 2504
42. J.D. Morrow, W.E. Zackert, J.P. Yang, E.H. Kurhts, D. Callewaert, and R. Dworski Quantification of the major urinary metabolite of 15-F2t-isoprostane (8-iso-PGF2alpha) by a stable isotope dilution mass spectrometric assay Anal. Biochem. 269 1999 326 331
43. C.R. Morales, E.S. Terry, W.E. Zackert, T.J. Montine, and J.D. Morrow Improved assay for the quantification of the major urinary metabolite of the isoprostane 15-F(2t)-Isoprostane (8-iso-PGF(2alpha)) by a stable isotope dilution mass spectrometric assay Clin. Chim. Acta 314 2001 93 99
44. W.R. Markesbery, and M.A. Lovell Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease Neurobiol. Aging 19 1998 33 36
45. J. Nourooz-Zadeh, E.H. Liu, E. Anggard, and B. Halliwell F4-isoprostanes: a novel class of prostanoids formed during peroxidation of docosahexaenoic acid (DHA) Biochem. Biophys. Res. Commun. 242 1998 338 344
46. L.J. Roberts 2nd, T.J. Montine, W.R. Markesbery, A.R. Tapper, P. Hardy, and S. Chemtob Formation of isoprostane-like compounds (neuroprostanes) in vivo from docosahexaenoic acid J. Biol. Chem. 273 1998 13605 13612
47. E.S. Musiek, J.K. Cha, H. Yin, W.E. Zackert, E.S. Terry, and N.A. Porter Quantification of F-ring isoprostane-like compounds (F4-neuroprostanes) derived from docosahexaenoic acid in vivo in humans by a stable isotope dilution mass spectrometric assay J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 799 2004 95 102
48. J. Nourooz-Zadeh, E.H. Liu, B. Yhlen, E.E. Anggard, and B. Halliwell F4-isoprostanes as specific marker of docosahexaenoic acid peroxidation in Alzheimer's disease J. Neurochem. 72 1999 734 740